Clinical Trial SuccessCellectis presented promising data from the Phase 1 BALLI-01 study with lasme-cel, showing a CR/CRi rate of 56% in heavily pretreated patients.
Manufacturing And Cost AdvantageLasme-cel is an anti-CD22 allogeneic CAR T cell therapy that is currently manufactured in-house by Cellectis, potentially offering cost advantages.
Research ProgressCellectis plans to report a data update with Eti-cel (UCART20x22) from the NATHALI-01 trial in r/r NHL, which may provide further insights into their research progress.